|Bid||178.00 x 200|
|Ask||203.00 x 100|
|Day's Range||183.10 - 192.45|
|52 Week Range||74.45 - 236.17|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Akcea Therapeutics (AKCA) is a late-stage biopharmaceutical company. AKCA’s pipeline includes volanesorsen, AKCEA-APO, AKCEA-ANGPTL, and AKCEA-APOCIII, which are based on Ionis Pharmaceuticals’ (IONS) antisense technology. In March 2018, two of the four analysts covering Akcea Therapeutics have given the stock “buy” or higher ratings, while two have given it “hold” ratings.
Bluebird bio Inc (NASDAQ: BLUE ), a clinical-stage biotechnology company that focuses on therapies for the treatment of severe diseases and cancer , released "highly encouraging" clinical data ...
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
Healthcare sector has proven itself to be one of the most resilient sectors of the US economy. Since healthcare cannot be outsourced and represents an expense that people usually cut on last during economic downturns, investing in healthcare stocks is a good way to recession-proof your portfolio. Moreover, the sector itself is comprised of many […]
Shares of bluebird bio Inc (NASDAQ: BLUE ) gained more than 200 percent in value last year and investors can expect 2018 to be another "blue-ribbon year" for the stock, according to William ...
The recent volatility in the global stock market may make some investors feel queasy, but it is providing a buying opportunity in biotechnology stocks. Bhaman, whose fund received a 2018 U.S. Thomson Reuters Lipper Fund Award in the global large-cap growth fund category in New York on Tuesday, is focusing on companies such as Sage Therapeutics Inc (SAGE.O), Bluebird Bio Inc (BLUE.O) and Ionis Pharmaceuticals Inc (IONS.O) whose drugs can have multiple uses rather than pinpointing a specific ailment.
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.52. The results missed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment ...
Bagging the first breakthrough therapy designation for a sickle cell disease modifying treatment boosted confidence last month.
Shares of bluebird bio Inc (NASDAQ: BLUE ) are up 360 percent over the last two years, but Leerink said the stock’s losing steam. The Rating Leerink analyst Michael Schmidt downgraded Bluebird from Outperform ...
Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.